Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Wuxi Biologics (Cayman) (OtherWXIBF) and Alkermes (ALKS)

Tipranks - Tipranks - Fri Apr 10, 7:52PM CDT

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Wuxi Biologics (Cayman) (WXIBF) and Alkermes (ALKS) with bullish sentiments.

Easter Sale - 70% Off TipRanks

Wuxi Biologics (Cayman) (WXIBF)

In a report issued on April 7, Laurence Tam from Morgan Stanley maintained a Buy rating on Wuxi Biologics (Cayman), with a price target of HK$50.00. The company’s shares closed last Wednesday at $4.60.

Tam has an average return of 3.2% when recommending Wuxi Biologics (Cayman). ;'>

According to TipRanks.com, Tam is ranked #9940 out of 12128 analysts.

Currently, the analyst consensus on Wuxi Biologics (Cayman) is a Strong Buy with an average price target of $5.91, implying a 28.5% upside from current levels. In a report issued on March 26, CMB International Securities also maintained a Buy rating on the stock with a HK$39.00 price target.

See today’s best-performing stocks on TipRanks >>

Alkermes (ALKS)

In a report released yesterday, Uy Ear from Mizuho Securities reiterated a Buy rating on Alkermes, with a price target of $53.00. The company’s shares closed last Thursday at $34.92, close to its 52-week high of $36.45.

According to TipRanks.com, Ear is a 1-star analyst with an average return of -0.6% and a 36.0% success rate. Ear covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, ACADIA Pharmaceuticals, and Cartesian Therapeutics. ;'>

Alkermes has an analyst consensus of Strong Buy, with a price target consensus of $44.64, implying a 27.5% upside from current levels. In a report issued on April 1, TD Cowen also maintained a Buy rating on the stock with a $40.00 price target.

Read More on WXIBF:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).